• Skip to primary navigation
  • Skip to main content
  • Skip to footer
Be Biopharma

Be Biopharma

Advancing our science with bold humanity

  • Investors & Media
    • News Releases
    • Publications & Presentations
  • Careers
  • Contact Us
  • Search
  • Our Company
    • About Be Bio
    • Life at Be Bio
    • Leadership
    • Board of Directors
    • Scientific Advisory Board
    • Investors
  • Our Science
    • About BCMs
    • Our Platform
    • Publications & Presentations
  • Patients & Caregivers
Home/Our Science

Unleashing nature’s manufacturing powerhouse.

B cells are nature’s exquisitely tuned medicine factories, manufacturing proteins to fight disease and maintain health. What if… we could engineer these cells to produce any therapeutic protein needed … allogeneically, without preconditioning, and redosably? The resulting new class of medicines – Engineered B Cell Medicines (BCMs) – could be transformative.

Powerful & Durable

In nature, a single B cell can produce thousands of proteins per second at constant levels over decades. Leveraging this inherent power, our BCMs could create previously impossible options for patients.

Precisely Engineered

B cells resist interference by outside agents and have been notoriously intractable to therapeutically relevant engineering. Until now. Our tunable, site-specific, precision genome engineering results in BCMs that produce proteins efficiently, with controlled, constant and consistent dosing (and redosing).

Easily Administered

Plasma cells, terminally differentiated B cells, have evolved to be able to more easily evade immune detection, and they intrinsically traffic to and engraft in the bone marrow. These properties drive the potential for powerful off-the-shelf medicines without the need for the toxic preconditioning required in other classes of cellular medicine.

Exceptionally Versatile

BCMs can be engineered to produce a vast array of therapeutically important biologics without the burdens of other cellular medicines, driving exceptionally broad therapeutic application — across protein classes, patient populations, and therapeutic areas.

Scientific Publications

View All

Molecular Therapy|February 6, 2025

In vivo tracking of ex-vivo-generated 89Zr-oxine-labeled plasma cells by PET in a non-human primate model

Read More about In vivo tracking of ex-vivo-generated 89Zr-oxine-labeled plasma cells by PET in a non-human primate model

ASH 2024|December 8, 2024

BeCoMe9-A Phase 1/2 Dose Escalation and Expansion Study of BE-101 for the Treatment of Adults with Moderately Severe or Severe Hemophilia B

Read More about BeCoMe9-A Phase 1/2 Dose Escalation and Expansion Study of BE-101 for the Treatment of Adults with Moderately Severe or Severe Hemophilia B

Learn more about what it’s like to be part of the team powering this platform.

Our Platform

Footer

Be Biopharma
LinkedIn X

info@be.bio

Contact Us

Careers

  • Our Company
    • About Be Bio
    • Life at Be Bio
    • Leadership
    • Board of Directors
    • Scientific Advisory Board
    • Investors
  • Our Science
    • About BCMs
    • Our Platform
    • Publications & Presentations
  • Patients & Caregivers
  • Investors & Media
    • News Releases
    • Publications & Presentations

©2023, Be Biopharma

Privacy Policy

logo
  • Our Company
    • About Be Bio
    • Life at Be Bio
    • Leadership
    • Board of Directors
    • Scientific Advisory Board
    • Investors
  • Our Science
    • About BCMs
    • Our Platform
    • Publications & Presentations
  • Patients & Caregivers
  • Investors & Media
    • News Releases
    • Publications & Presentations
  • Careers
  • Contact Us